BP

Biohaven Pharmaceutical

New Haven, US

About

Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

Position in the VCSift Database

  • 3,884 investors in VCSift focus on the healthtech sector.
  • 58 investors are based in New Haven, Connecticut, United States.

Data sourced from 410,343 investor profiles. Updated July 2026.

Investment Focus

Contact Information

em••••@example.com
linkedin.com/in/••••••••

Unlock contact details with a VCSift subscription

Unlock Contact

Already subscribed? Log in

Find more investors like Biohaven

Search Investors